LLY Stock Forecast: When Great Isn’t Cheap

This LLY Stock Forecast article was written by Fu Kang Wong – Financial Analyst at I Know First.

Highlights

  • GLP-1 leadership drives long-term growth.
  • Current valuation exceeds intrinsic value.
  • Sell recommendation due to limited upside.

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

LLY Stock Forecast: Mounjaro Momentum

Milana PapadopoulouThis LLY Stock Forecast article was written by Milana Papadopoulou – Financial Analyst at I Know First.

Highlights

  • Eli Lilly posts over 40% revenue growth in 2025, led by GLP-1 therapies Mounjaro and Zepbound
  • Cardiometabolic drugs drive nearly three-quarters of total revenue
  • Novo Nordisk remains the main competitor in diabetes and obesity drugs

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here